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Abstract 
 
Cryptosporidium is an enteric protozoan parasite that causes gastrointestinal disorders in humans and in a wide range 
of animals, mainly in calves. As there is no available efficient treatment for cryptosporidiosis, in this study we evaluated 
the effect of Auranta 3001, a natural feed additive on animal growth, number of days with liquid diarrhoea and oocyst 
excretion, mean oocysts/gram faeces and on biochemical and physical parameters. The study showed that calves fed 
with Auranta 3001 as a feed additive administered prior to infection with C. parvum, significantly reduced (P < 0.05) 
the number of days with liquid diarrhoea, the number of days with oocyst excretion, the number of days of antibiotic 
administration and mean oocysts/gram faeces. Moreover, the prophylactic administration of Auranta 3001, 
significantly (P < 0.05) reduced the percentage of calves with fever and increased the body weight at day 56. However, 
significant differences were not seen between IgG, total protein intake and haematocrit percentage. This study showed 
the efficacy of Auranta 3001 in reducing cryptosporidiosis manifestations in calves. 
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INTRODUCTION 
 
The protozoan parasite Cryptosporidium sp. is 
the worldwide leading cause of diarrhoea in 
young calves of less than 6 weeks old, 
alongside with Rotavirus, Coronavirus and 
enterotoxigenic Escherichia coli K99 
(Arsenopoulos et al., 2017; Cho and Yoon, 
2014; Smith et al., 2014). During the first 
month of life, diarrhoea causes the syndrome of 
maldigestion and malabsorption which leads to 
delayed growth, increased morbidity and 
mortality, which can be up to 50% of weaning 
calves, having a direct and indirect negative 
economic impact in the farming industry (Cho 
and Yoon, 2014; Bartels et al., 2010; Gulliksen 
et al., 2009).  
Once ingested, C. parvum oocysts release 
sporozoites that initially attach to the 
membrane of the epithelial cells, then it 
penetrates the small intestine wall where it 
resides for most of its life cycle. The ongoing 
infections can lead to increased intestinal 
damage and secretory diarrhoea (Yang et al., 
2015; Cho and Yoon, 2014). The severity of 
the disease manifestation in humans and 
animals can vary depending on the C. parvum 
isolate as well as host predisposing factors 
(Enemark et al., 2003). In calves, 
cryptosporidiosis is mostly endemic, with more 
than 90% of dairy farms and 40% of beef farms 
being contaminated (Chako et al., 2010). The 
prevalence of C. parvum varies between 
countries, regions and farms. For example, in 
the UK, cryptosporidiosis in cattle dairy farms 
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range between 28% and 80% (Thomson et al., 
2017; Smith et al., 2014). C parvum is reported 
to prevail among pre-weaned calves from 3.4% 
to 96.6% in different parts of the world 
(Thomson et al., 2017). In calves, the European 
Medicines Agency has approved only 
halofuginone lactate as an effective drug 
against Cryptosporidium spp., though it does 
not treat the disease and shows limited and 
temporary benefits in reducing infection or 
animal production (Connor et al., 2017; Chavez 
and White, 2018; Caccio and Chalmers, 2016).  
In contrast to chemotherapeutics, the use of 
natural antimicrobials as feed supplements, 
active against Cryptosporidium spp. could 
represent a new and safe approach in 
pharmacotherapy of cryptosporidiosis 
(Valigurova et al., 2018). The aim of the 
present study was to investigate the efficacy of 
a combination of natural extracts for the 
prophylaxis and treatment of cryptosporidiosis 
in calves. 
 
MATERIALS AND METHODS 
 
Parasites 
Cryptosporidium parvum oocysts were 
obtained from the American Type Culture 
Collection. Oocysts were stored in phosphate-
buffered saline (PBS) at 4°C until use. Before 
use, they were incubated for 15 min in sodium 
hypochlorite (4%) at 4°C and washed (3x) with 
cold D-PBS (Dulbecco’s phosphate buffered 
saline, Sigma, UK) followed by centrifugation 
for 10 min at 2500×g. Subsequently, the pellet 
was suspended in 1 ml D-PBS and the number 
of oocysts was determined using a 
haemocytometer.  
 
Phytochemicals 
The novel feed additive (Auranta 3001) was 
supplied by Auranta-Envirotech Innovative 
Products Ltd and contains lactic and citric acid, 
glycerine-based emulsifying agent, sodium 
hydroxide, sodium chloride, citrus extract 
(6%), grape seed extract (2%), oregano extract 
(1%). 
 
Artificial infection 
The feed additive, Auranta 3001, was provided 
to three calves, later included in the uninfected 
treatment group, for a period of 20 days 
starting from day 1 after their arrival at the 
farm. On day 0, nine calves were randomly 
assigned to three additional experimental 
groups and inoculated with 1x107 C. parvum 
oocysts (three calves per group). In the 
prophylactic group, Auranta 3001 was 
administered prior to infection and then on a 
daily basis for a period of 20 days. The 
therapeutic group, was provided with Auranta 
3001 starting at the time point of the first 
manifestation of diarrhoea and then daily for a 
period of 20 days. The calves of the infection 
control group (3rd group), were left untreated. 
Preparation of inoculum and viable oocysts 
count was done as previously described 
(Anguish and Ghiorse, 1997; Jenkins et al., 
1997). The feed additive was provided to the 
animals at a concentration of 25 ml/day for the 
first 5 days and 10 ml/day after day 5. Auranta 
3001 was fed through a suckling bottle with 
milk replacer twice daily.  
 
Sample analysis 
Analysis of C. parvum oocysts in faecal 
samples was performed according to Bellosa et 
al. (Bellosa et al., 2011). On days 0, 28 and 56, 
blood was taken from the jugular vein, using 
collection tubes without anticoagulant. The 
whole blood was centrifuged at 3500 rpm × 10 
min. Supernatants (serum samples) were stored 
at - 20°C until analysis. We measured plasma 
levels of total protein, albumin, urea, 
cholesterol, glucose and triglycerides using 
commercial kits using a BioPlus 2000® device. 
The levels of serum globulin was determined 
as total serum protein minus serum albumin. 
Rectal faecal samples were collected from the 
calves and faecal consistency was determined 
according to Grinberg et al. (Grinberg et al., 
2002). Comparison between treated and control 
groups was done using Student’s t-test, with a 
significance level of 0.05. 
 
RESULTS AND DISCUSSIONS 
 
Cryptosporidium sp. is a major cause of 
gastroenteritis in humans and animals. The 
protozoan parasite represents a highly 
problematic target for drug development 
(Checkley et al., 2015; Farthing, 2006; Tzipori 
et al., 1982). The only licensed drug for 
treatment of cryptosporidiosis in calves is 
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halofuginone lactate which is extremly toxic to 
multiple organs and systems at effective doses 
(Tzipori, 1998; Yvore and Naciri, 1989). 
Besides this, numerous substances like, 
paromomycin and nitazoxanide have been 
screened for potential anti-cryptosporidial 
activity in calves, but they showed no 
therapeutic effect (Fayer and Ellis, 1993; 
Grinberg et al., 2002; Theodos et al., 1998; 
Schnyder et al., 2009; Ollivett et al., 2009). 
Recently, the attention has been drawn towards 
plant extracts as an alternative remedy with 
anti-cryptosporidial activity. Punica granatum, 
Allium sativum extracts and curcumin have 
been shown to reduce faecal oocyst count, 
diarrhoea intensity and duration in neonatal 
calves and BALB/c mice (Weyl-Feinstein et 
al., 2014; Al-Mathal and Alsalem, 2012; 
Gaafar, 2012; Asadpour et al., 2018). In vitro, 
Auranta 3001 has been shown to reduce the 
invasiveness of C. hominis and C. parvum 
against HCT-8 and bovine primary cells and to 
reduce the virulence by downregulating 
CpSUB1 gene expression (Ch Stratakos et al., 
2017). The efforts to explore the in vivo 
efficacy of Auranta 3001 were undertaken. 
Auranta 3001 is a natural feed supplement 
consisting of a mixture of organic acids and 
plant extracts. Therefore, its anti-
cryptosporidial potential was examined in the 
present study in calves by assessing the number 
of days with liquid diarrhoea, number of days 
with oocyst excretion, mean OPG, biochemical 
and physiological parameters. 
 
The effect of the novel additive (Auranta 
3001) on calves naturally infected with 
Cryptosporidium parvum 
We have started with 61 calves in the control 
group and 58 calves in the treatment group 
enrolled in the study. By the end of the 
experiment (56 days), 4 calves from the control 
group died due to severe diarrhoea and 
exhaustion. However, no mortalities were over 
the entire 56 days study in the treatment group. 
By comparing the indices of animal health in 
the naturally infected calves, control and 
treated with the novel feed supplement, we can 
observe that overall the values of those treated 
were lower than those which were not given 
Auranta 3001. Specifically, the percentage of 
scouring calves and the number of days with 
scours during the study was significantly lower 
(P < 0.05) in the treated group when compared 
to the control group (Table 1).  
 
Table 1. Comparison of physiological and biochemical parameters between the control  
and treatment group of naturally infected calves 
 Control group SD Treatment group SD 
Scours (percentage of calves) 78.2 6.5 16.2* 0.3 
Scours (duration in days) 7.2 0.5 4.8* 1.7 
Faecal scores 2.44 0.08 1.28 0.2 
Fever (percentage of calves) 45.8 0.2 14.3* 7.1 
IgG (g/L) 8.1 0.5 8.5 0.6 
Haematocrit (percentage) 31.0 1.0 32.8 1.0 
Total protein (g/L) 58.3 0.8 59.6 0.05 
Antibiotics (percentage of calves) 46.7 0.1 21.2 0.1 
      * indicates significance (p < 0.05); SD: standard deviation 
 
The growth performance analysis of the 
calves indicated that initial body weights 
(BW) at day 0 were similar. On day 56 a 
significantly higher BW difference (P < 0.05) 
was observed in calves fed with Auranta 3001 
(79.3 ± 0.5 kg) compared to the control group 
(72.7 ± 1.22 kg). The average daily weight 
gain in the period of acute infection (day 0-
day 28) was twice as high in animals from the 
treatment group. In the convalescence period 
(day 29-day 56) the animals from both groups 
gained similar body weight. In the treatment 
group, the calves had a bigger affinity 
towards protein and glucose intake and hence 
increased levels of IGF-1 and urea.  Plasma 
concentrations of TNF-α and growth hormone 
were unaffected by the dietary supplement (P 
> 0.05). 
 
Effect of the Auranta 3001 on artificially 
infected calves 
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Altered faecal consistency and particularly 
diarrhoea was observed in all animals, though 
different in duration and severity (Table 2) 
between prophylactic, therapeutic and control 
groups. Prophylactic administration of 
Auranta 3001 has had more beneficial effect 
in reducing the number of days with liquid 
diarrhoea in calves hence it helped to 
significantly avoid the complications (p < 
0.05). The effect of Auranta 3001 was further 
investigated on the number of days with 
oocyst excretion and number of oocysts shed 
[sum of the daily OPG (oocysts per gram of 
faeces) per calf] in all groups. The 
prophylactic administration of Auranta 3001 
has had the most beneficial effect upon 
reducing the number of oocysts shed 
(0.04x102 OPG) and also the number of days 
(2 days) of oocyst excretion compared to the 
therapeutic (12.33 days) and the control 
groups (12 days). The number of oocysts shed 
and the daily mean OPG value was 
significantly lower (P < 0.05) in the 
prophylactic group compared to therapeutic 
and control groups. All calves tolerated 
Auranta 3001 treatment without compound 
related abnormalities. 
 
Table 2. Effect of Auranta 3001 on the parameters of faecal consistency, number of days with  
observed oocyst excretion and mean OPG of calves artificially infected with Cryptosporidium oocysts 
 No. of animals No. of days where 
semi-solid faecal 
consistency 
No. of days 
were diarrhoea 
was observed 
No. of days with 
observed oocyst 
excretion 
Oocysts/gram of 
faeces 
Uninfected* Animal 1 4 6 0 0 
Animal 2 4 6 0 0 
Animal 3 5 5 0 0 
Average 4.33  5.66 0 0 
Prophylactic 
group** 
Animal 4 11 2 3 0.015x102 
Animal 5 15 1 1 0.012x102 
Animal 6 9 1a 2 0.1x102 
Average 11.66 1.33 2 0.04x102b 
Therapeutic 
group*** 
Animal 7 3 8 11 4.2x106 
Animal 8 4 9 14 3.4x106 
Animal 9 3 6 12 5.1x106 
Average 3.33 7.66 12.33 4.23x106 
Control group**** Animal 10 1 12 13 1.2x108 
Animal 11 2 9 11 2.4x108 
Animal 12 1 11 12 3.1x108 
Average  1.33 10.66 12 2.23x108 
ap<0.05: paired t test with control group 
*Animals not infected but Auranta administered 
**Auranta administered prior to inoculation (day 1) and then daily for 20 days 
*** Calves received Auranta at the time point of the first manifestation of diarrhoea and then daily for a period of 20 days 
****Infected but NO Auranta administered 
- On day 0 animals were inoculated with 1x107 C. parvum oocysts 
 
The results of the study showed that 
prophylactic administration of Auranta 3001 
significantly (P < 0.05) increased the number of 
days with semi-solid faecal consistency. In 
contrast with a study conducted by Schnyder et 
al. (Schnyder et al., 2009) on nine calves, the 
effect of nitazoxanide administered as a 
therapeutic and prophylactic treatment showed 
an increased number of days with liquid 
diarrhoea when compared with the infected but 
untreated control group.  
The number of days with oocyst excretion and 
the mean OPG value were significantly lower 
(P < 0.05) in the prophylactic group when 
compared to the therapeutic and control groups. 
The number of days with oocyst excretion in 
the therapeutic group was similar to the 
untreated control group. Our findings showed 
that the prophylactic administration of the 
novel feed supplement could stop oocyst 
shedding without recurrence within 3-4 days 
after the infection.  
Similar findings were described with 
halofuginone lactate administration as a 
prophylactic and therapeutic treatment, where 
the shedding of oocysts and the number of 
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scours (expression of diarrhoea) were 
significantly reduced at 4 and 7 days of age, but 
higher after 21 days of age, when compared to 
control (Trotz-Williams et al., 2011). The 
opinions on halofuginone lactate are 
controversial, as some researchers have found 
that a concentration of 0.1 mg/kg BW is 
increasing the number of scours per day (De 
Waele et al., 2010)  and some have found that 
calves who are reared in good hygienic 
conditions, such as disinfected individual calf 
pens, halofuginone lactate was effective in 
delaying the onset of Cryptosporidium 
infection and diarrhoea, in reducing the number 
of calves that become infected and exhibit 
signs of enteritis, and decreasing the level of 
oocysts excretion (De Waele et al., 2010, 
Klein, 2008). In this study, the plasma urea 
concentration did not differ between the control 
and treatment groups, as the protein intake was 
similar in both of the tested groups.  
 
CONCLUSIONS 
 
In conclusion, our findings have shown that 
Auranta 3001 significantly reduced the number 
of days with diarrhoea, the number of C. 
parvum oocysts shed by calves and overall 
increased the general health of the calves. 
Therefore, the feed supplement could be 
considered as an effective alternative against 
cryptosporidiosis. 
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